Four US drug companies pay $124m for defrauding MedicaidBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b4500 (Published 29 October 2009) Cite this as: BMJ 2009;339:b4500
- Janice Hopkins Tanne
- 1New York
Four US drug companies have made settlements with the US Department of Justice and agreed to pay $124m (£75m; €84m) to resolve false claims that they submitted to the US Medicaid programme after a whistleblower complained.
The companies were Mylan Pharmaceuticals and UDL Laboratories, which paid $118m; Astra Zeneca, which paid $2.6m; and Ortho McNeil, which paid $3.4m.
The amount recovered by the US government will be shared between the federal government, the states, the Public Health Service’s drug pricing programme, and the whistleblower.
“The [US federal] False Claims Act allows a citizen [a whistleblower] to bring fraud to the attention of the government. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial